Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Galcanezumab (Primary)
- Indications Cluster headache; Migraine
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 04 Dec 2017 Planned End Date changed from 31 Mar 2018 to 1 Jan 2018.
- 11 Jun 2017 Results of part A and part B, presented at the 59th Annual Scientific Meeting of the American Headache Society.